磷脂酰肌醇
激酶
癌症研究
医学
内科学
化学
生物
细胞生物学
作者
Christian Schnell,Frédéric Stauffer,Peter Roland ALLEGRINI,Terence O’Reilly,Paul M.J. McSheehy,Celine Dartois,Michael Stumm,Robert M. Cozens,Amanda J. Littlewood-Evans,Carlos Garcia-Echeverria,Sauveur-Michel Maira
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2008-08-12
卷期号:68 (16): 6598-6607
被引量:190
标识
DOI:10.1158/0008-5472.can-08-1044
摘要
Dysregulated angiogenesis and high tumor vasculature permeability, two vascular endothelial growth factor (VEGF)-mediated processes and hallmarks of human tumors, are in part phosphatidylinositol 3-kinase (PI3K) dependent. NVP-BEZ235, a dual PI3K/mammalian target of rapamycin (mTOR) inhibitor, was found to potently inhibit VEGF-induced cell proliferation and survival in vitro and VEGF-induced angiogenesis in vivo as shown with s.c. VEGF-impregnated agar chambers. Moreover, the compound strongly inhibited microvessel permeability both in normal tissue and in BN472 mammary carcinoma grown orthotopically in syngeneic rats. Similarly, tumor interstitial fluid pressure, a phenomenon that is also dependent of tumor permeability, was significantly reduced by NVP-BEZ235 in a dose-dependent manner on p.o. administration. Because RAD001, a specific mTOR allosteric inhibitor, was ineffective in the preceding experiments, we concluded that the effects observed for NVP-BEZ235 are in part driven by PI3K target modulation. Hence, tumor vasculature reduction was correlated with full blockade of endothelial nitric oxide (NO) synthase, a PI3K/Akt-dependent but mTORC1-independent effector involved in tumor permeability through NO production. In the BN472 tumor model, early reduction of permeability, as detected by K(trans) quantification using the dynamic contrast-enhanced magnetic resonance imaging contrasting agent P792 (Vistarem), was found to be a predictive marker for late-stage antitumor activity by NVP-BEZ235.
科研通智能强力驱动
Strongly Powered by AbleSci AI